Regeneron announced updated long-term Phase 3 data for Libtayo in high-risk CSCC, showing a further reduction in the risk of death despite significant crossover from the control arm. This positive clinical trial update reinforces the drug's efficacy and potential for increased market penetration and revenue for Regeneron.
Regeneron announced updated long-term results from its Phase 3 C-POST trial for Libtayo in high-risk CSCC, demonstrating a further reduction in the risk of death over nearly four years. This is significant because it provides stronger evidence of Libtayo's long-term efficacy and overall survival benefit, even with a high crossover rate from the control arm, which typically dilutes observed differences. This positive data could lead to increased adoption of Libtayo in the adjuvant CSCC setting, benefiting Regeneron through higher sales and market share. For traders, this represents a positive catalyst for REGN stock, reinforcing its competitive position in oncology and potentially driving short-term price appreciation, with long-term implications for sustained revenue growth.